Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …

… In this study, patients with plaque psoriasis who remained on tofacitinib maintained
significantly better efficacy than those who stopped treatment. The low median PASI scores in …

… plaque psoriasis. It has a composite score ranging from 0·0 to 72·0 that comprises the degree
of body surface area affected by psoriasis, … of overall psoriasis severity (plaque elevation, …

… A total of 507 eligible patients had stable moderate to severe chronic plaque psoriasis for
6 months or longer, body surface area involvement greater than or equal to 10%, Psoriasis …

… psoriasis require long‐term therapy, 2 creating a critical need for psoriasis treatments that
not only clear psoriasis plaques … the time to relapse after drug withdrawal remains a concern. …

… Furthermore, analysis of an international psoriasis registry … Many patients with psoriasis stop
and restart treatment … study of patients with long‐term plaque psoriasis found that, over a 12‐…

… in the treatment of moderate‐to‐severe plaque psoriasis in a phase II clinical trial.15 This …
withdrawal/retreatment of brodalumab in patients with moderate‐to‐severe plaque psoriasis…

… did not prevent psoriasis relapse that occurred after ustekinumab withdrawal because it
did not completely block the pathogenic psoriasis molecular pathways that led to relapse. …

… ‐17A antibody, in moderate‐to‐severe plaque psoriasis in a phase II regimen‐finding study.
… The primary outcome was ≥ 75% improvement from baseline Psoriasis Area and Severity …

… In the current report of the RESTORE2 trial, patients with moderate‐to‐severe plaque
psoriasis underwent a 10‐week induction course with infliximab 5 mg kg −1 plus two rounds of …